196 related articles for article (PubMed ID: 9272133)
21. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI
J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027
[TBL] [Abstract][Full Text] [Related]
22. CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.
Chim CS; Kwong YL; Lie AK; Lee CK; Liang R
Hematol Oncol; 1998 Sep; 16(3):117-23. PubMed ID: 10235070
[TBL] [Abstract][Full Text] [Related]
23. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
[TBL] [Abstract][Full Text] [Related]
24. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
Okabe M; Maekawa I; Suzuki S; Higuchi M; Morioka M; Nishi K; Itaya T; Ohmura T; Kawamura M; Fuzimoto N
Leuk Lymphoma; 1995 Nov; 19(5-6):485-91. PubMed ID: 8590851
[TBL] [Abstract][Full Text] [Related]
25. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
27. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
28. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
29. Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group.
Miller TP; Dahlberg S
Cancer Treat Res; 1993; 66():53-63. PubMed ID: 8102863
[TBL] [Abstract][Full Text] [Related]
30. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Wolf M; Matthews JP; Stone J; Cooper IA; Robertson TI; Fox RM
Ann Oncol; 1997; 8 Suppl 1():71-5. PubMed ID: 9187435
[TBL] [Abstract][Full Text] [Related]
34. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
[TBL] [Abstract][Full Text] [Related]
35. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
[TBL] [Abstract][Full Text] [Related]
36. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
[TBL] [Abstract][Full Text] [Related]
37. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
[TBL] [Abstract][Full Text] [Related]
38. Results of CHOP chemotherapy for diffuse large B-cell lymphoma.
Hallack Neto AE; Pereira J; Beitler B; Chamone DA; Llacer PD; Dulley FL; Macedo MC; Chaoubah A
Braz J Med Biol Res; 2006 Oct; 39(10):1315-22. PubMed ID: 16906323
[TBL] [Abstract][Full Text] [Related]
39. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
40. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ
Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
